Jennifer Dorn
Family · Camp Verde, AZNPI 1376105171
Payments from drug & device makers
Across 128 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$278
- AbbVie$256
- Sanofi-aventis U.S. LLC$223
- GSK$180
- Amgen$179
- Lilly USA, LLC$165
- plus $941 from 21 others
What the payments were for
- Food & beverage$2,221100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 16 | $278 |
| AbbVie | 13 | $256 |
| Sanofi-aventis U.S. LLC | 11 | $223 |
| GSK | 11 | $180 |
| Amgen | 11 | $179 |
| Lilly USA, LLC | 12 | $165 |
| Johnson & Johnson | 8 | $118 |
| Astellas Pharma US Inc | 6 | $115 |
| AstraZeneca | 6 | $84 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $73 |
| Novo Nordisk | 4 | $68 |
| Boston Scientific | 3 | $62 |
| Merck | 3 | $54 |
| Dexcom, Inc. | 2 | $50 |
| Boehringer Ingelheim | 3 | $47 |
| Phadia US Inc. | 2 | $42 |
| Biohaven Pharmaceuticals, Inc. | 2 | $28 |
| Tactile Systems Technology Inc | 1 | $27 |
| Mannkind Corporation | 2 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Medtronic | 1 | $22 |
| Bayer | 1 | $22 |
| Exact Sciences | 1 | $19 |
| Nevro Corp. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
How this compares
$2,221 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 68 | $69,943 |
| OzempicSemaglutide | 53 | $60,655 |
| EliquisApixaban | 42 | $36,820 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $33,412 |
| FarxigaDapagliflozin Propanediol | 25 | $17,280 |
| XareltoRivaroxaban | 13 | $15,853 |
| TrulicityDulaglutide | 12 | $15,699 |
| JardianceEmpagliflozin | 16 | $12,749 |
| VascepaIcosapent Ethyl | 19 | $12,734 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $9,776 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 113 | $3,629 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $2,829 |
| Levothyroxine Sodium | 245 | $2,624 |
| Rosuvastatin Calcium | 81 | $2,061 |
| Gabapentin | 133 | $1,966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $165 | $85,64280 claims |
| Novo NordiskOzempic | $68 | $60,65553 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $180 | $43,18874 claims |
| PfizerEliquis | $278 | $36,82042 claims |
| AstraZenecaFarxiga | $84 | $17,28025 claims |
| Johnson & JohnsonXarelto | $118 | $15,85313 claims |
| Boehringer IngelheimJardiance | $47 | $12,74916 claims |
| AbbVieArmour Thyroid, Synthroid | $256 | $2,94432 claims |
| Sanofi-aventis U.S. LLCLantus | $223 | $1,16717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.
Other family in Camp Verde
- Sharon MagalonaMesa$449K
- Angela GoldenMunds Park$378K
- Kimberly HallaPhoenix$332K
- Kaitlyn LouchheimScottsdale$208K
- Rebecca McCollaumMesa$149K
- Susan SarabiaSun City West$114K
- Lindsay CarterTucson$108K
- Audrey StevensonPhoenix$83K
- Keith MorsePrescott$83K
- Celeste FineGilbert$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.